ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY

William Sandborn  1     Julian Panés  2     Silvio Danese  3     Zaineb Sharafali  4     Azra Hassanali  4     Rhian Jacob  5     Chistopher Eden  5     Marco Daperno  6     John F. Valentine  7     David Laharie  8     Carolina de Paula Guimarães Baía  9     Raja Atreya  10     Remo Panaccione  11     Grazyna Rydzewska-Wyszkowska  12     Humberto Aguilar  13     Severine Vermeire  14    
1 University of California San Diego, San Diego, United States
2 Hospital Clínic Barcelona, Barcelona, Spain
3 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
4 Genentech, Inc., South San Francisco, United States
5 F. Hoffmann-La Roche AG, Basel, Switzerland
6 Gastroenterology Unit, A.O. Mauriziano “Umberto I”, Torino, Italy
7 University of Utah, Salt Lake City, United States
8 CHU de Bordeaux Hopital Haut-Leveque Dept. de Gastroenterologie, Pessac cedex, France
9 Médica Gastroenterologista em Belo Horizonte, Minas Gerais, Brazil
10 University Erlangen-Nuremberg, Erlangen, Germany
11 University of Calgary, Calgary, Canada
12 Centralny Szpital Kliniczny MSW w Warszawie, Warsaw, Poland
13 GastroIntestinal Specialists, Shreveport, United States
14 University Hospital Leuven, Leuven, Belgium

Topic
IBD, Nurses, Primary Care

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing